This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sanofi Expands Use Of Medidata’s Cloud-Based Platform To Advance Cutting-Edge Clinical Development

Stocks in this article: MDSO

Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Sanofi, one of the world’s top pharmaceutical companies, has increased its adoption of the Medidata Clinical Cloud™ as part of a company-wide initiative to achieve cutting-edge productivity across its global R&D organization. Sanofi, a Medidata enterprise client, will now leverage Medidata’s best-in-class technology for risk-based monitoring of clinical trial sites, in addition to the broad set of solutions and analytics already used through the Medidata platform to improve operational efficiencies, resource savings and decision making.

As a founding member of TransCelerate BioPharma Inc. —a non-profit organization dedicated to improving the health of people worldwide by accelerating and simplifying the R&D of innovative new therapies through industry collaboration—Sanofi is engaged in developing an industry-wide approach for targeted monitoring of clinical trial sites to enhance productivity while protecting patient safety and data quality. The company has conducted risk-based monitoring for the past several years and selected Medidata’s targeted source document verification ( Medidata Rave® TSDV) capability to provide an efficient, scalable and auditable technology solution for its clinical operations and data management teams.

“We’re proud that Medidata’s cloud-based platform is supporting Sanofi in driving the effective and high-quality delivery of new medicines to patients worldwide,” said Glen de Vries, president of Medidata. “Sanofi is an early adopter of risk-based monitoring practices and has been quick to implement TransCelerate’s recommendations on this important methodology, streamlining the way clinical trials are conducted and monitored around the world.”

In 2012, Sanofi adopted Medidata’s cloud-based technology for electronic data capture and management (EDC), safety data collection, medical coding, clinical business analytics and industry benchmarks. The addition of Rave TSDV—the solution unified with Medidata’s technology platform to support risk-based monitoring—provides Sanofi’s research teams with flexible tools that reduce timelines, increase productivity and provide quick access to meaningful data.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs